Loss of hepatocyte Ppara leads to hepatic steatosis due to impaired fatty acid catabolism (1), while activation improves steatohepatitis in models of metabolic dysfunction-associated steatotic liver disease (MASLD) (2). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.